Y-mAbs Therapeutics, Inc.

trial activity in the U.S. We believe Danielza will continue to grow in future periods, and this will not have a material impact on our cash flow guidance. We believe that Danielza will return to higher growth rates in the second half of 2024 as we execute our refined commercial strategy and work to deliver new clinical data that potentially could lead to expanded indications and greater physician adoption. In terms of development activities, we have assumed that all of our programs will be advancing at our own expense. No new programs other than the ones that are planned and in studies and trials are assumed at this point for the purposes of this analysis. With a strong balance sheet and a focused strategy, we believe BiMABS is well positioned to execute on our strategic mission and priorities and to support the delivery of multiple anticipated milestones as we move ahead.

This concludes the financial update, and now I will turn the call back over to Mike. Thank you for that overview, Pete. Now let's open the line for questions. Operator?

Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. We ask that analysts limit yourself to one question and a follow-up so that others may have an opportunity to ask questions. You may re-queue if you have additional questions. For participants using speaker equipment, it may be necessary to pick up your handsets before pressing the star key. One moment, please, while we poll for questions. Our first question comes from with BMO Capital Markets. Please proceed with your question.